Association between selective serotonin and serotonin-noradrenaline reuptake inhibitor therapy and hematuria

Basit Öğe Kaydı
dc.authoridMehmet Sarıer / 0000-0002-8656-7416
dc.authorscopusidMehmet Sarıer / 57193698943
dc.authorwosidMehmet Sarıer / B-8589-2018
dc.contributor.authorSarıer, Mehmet
dc.contributor.authorDemir, Meltem
dc.contributor.authorEmek, Mestan
dc.contributor.authorÖzgen, Ali
dc.contributor.authorTurgut, Hasan
dc.contributor.authorÖzdemir, Candan
dc.date.accessioned2022-03-07T13:51:02Z
dc.date.available2022-03-07T13:51:02Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Diyaliz Bölümüen_US
dc.description.abstractBackground: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are used as first-line treatment for many psychiatric diseases, especially major depressive disorder. However, an important side effect of these drugs is the risk of bleeding due to platelet dysfunction. The aim of this study was to determine the frequency of hematuria in patients using SSRI/SNRIs and to compare with a control group. Methods: This study included patients who were followed up and treated with SSRI/SNRI in the psychiatric outpatient clinic of the Antalya Medical Park Hospital between 1 January 2021 and 31 March 2021 and a control group comprising patients who presented to the medical check-up outpatient clinic between the same dates. Complete urinalysis was performed for all patients and the results were compared between the groups. Results: Each group included 100 patients with a female/male ratio of 1. The mean age was 41.45 ± 13.47 (16-74) years in the study group and 40.51 ± 13.75 (20-70) years in the control group (p = 0.519). Mean duration of SSRI/SNRI use in the study group was 13.35 ± 1.32 (1-64) months. The prevalence of hematuria was 17% in the SSRI/SNRI group and 6% in the control group (p = 0.015). All cases of hematuria were microscopic hematuria. Conclusion: Hematuria is significantly more common in patients receiving SSRI/SNRI treatment. The use of SSRI/SNRI should also be taken into account when investigating the etiology of hematuria.en_US
dc.identifier.citationSarier M, Demir M, Emek M, Özgen A, Turgut H, Özdemir C. Association between selective serotonin and serotonin-noradrenaline reuptake inhibitor therapy and hematuria. Nord J Psychiatry. 2022 Mar 4:1-5.en_US
dc.identifier.doi10.1080/08039488.2022.2047224en_US
dc.identifier.endpage5en_US
dc.identifier.pmid35243962en_US
dc.identifier.scopus2-s2.0-85126035280en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1080/08039488.2022.2047224
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2530
dc.identifier.wosWOS:000764929900001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorSarıer, Mehmet
dc.language.isoenen_US
dc.relation.ispartofNord J Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSNRIen_US
dc.subjectSSRIen_US
dc.subjectAntidepressantsen_US
dc.subjectHematuriaen_US
dc.subjectMicroscopic Hematuriaen_US
dc.titleAssociation between selective serotonin and serotonin-noradrenaline reuptake inhibitor therapy and hematuriaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
08039488.2022.pdf
Boyut:
876.98 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Diyaliz Programı Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu